Oncolytics Biotech (ONC.TO), down 4.6% in U.S. pre-market trading, on Tuesday said it has obtained safety and regulatory clearance in Germany for pelareorep to advance enrollment in its pancreatic cancer study. Thirty patients are set to participate in Stage 1 across the two treatment arms.
Oncolytics also said it presented new efficacy and safety data at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in late January.
"We're hitting critical milestones that validate our progress and set the stage for what we believe will be an exciting year," said Wayne Pisano, interim chief executive and the board chair. "With positive feedback from regulators in place, we're advancing our pancreatic cancer study toward full enrollment, and our ASCO GI presentations highlighted pelareorep's strong safety and efficacy results in two hard-to-treat cancers. We remain focused on bringing new treatment options to patients while creating value for shareholders as we move forward in 2025."
The company over the holiday weekend said it received a Nasdaq delinquency notification letter for failing to meet the minimum bid price requirement of US$1.00 for 30 consecutive business days. The company has 180 days to regain compliance with the price requirement.
Oncolytics was last seen down US$0.04 to US$0.73 in New York trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.